Heclin is primarily used in research settings as a selective inhibitor of the HECT (Homologous to E6-AP C-Terminus) family of E3 ubiquitin ligases. By targeting these enzymes, Heclin helps modulate the ubiquitin-proteasome system, which plays a critical role in protein degradation within cells. This makes it a valuable tool for studying cellular processes such as protein turnover, signal transduction, and regulation of cell cycle progression.

In experimental biology, Heclin has been applied to investigate pathways involving oncoproteins and tumor suppressors, offering insights into potential cancer therapeutics. It is also used to explore neurodegenerative diseases where abnormal protein accumulation is a hallmark, helping researchers understand how impaired ubiquitination contributes to disease progression. Due to its specificity, Heclin supports the development of targeted therapies that aim to restore normal ubiquitin ligase activity in diseased cells.